HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Progression of HIV disease among women following delivery.

AbstractOBJECTIVE:
To assess patterns of HIV disease progression among HIV-1-infected women following delivery.
METHODS:
Four hundred ninety-seven women enrolled in PACTG 185, a phase 3 trial of passive immunoprophylaxis in addition to zidovudine (ZDV) for the prevention of perinatal transmission, were included. Visits occurred twice during pregnancy; at delivery; and at 12, 26, 48, and 78 weeks postpartum. Repeated-measures linear regression and proportional hazards models were applied.
RESULTS:
Trial treatment (HIV hyperimmune globulin vs. immune globulin) was not related to postpartum disease progression. Longitudinal analysis of HIV-1 RNA demonstrated stable levels during pregnancy, significantly increased HIV-1 RNA by 12 weeks postpartum even on stable therapy, and a gradual increase thereafter. Changes in CD4+ lymphocyte percentage over 18 months of follow-up were similar for women continuing or stopping ZDV postpartum. Compared with those receiving no therapy, the hazard ratio for AIDS or death among women who received monotherapy postpartum was 0.52 (95% confidence interval [CI]: 0.25-1.04), 0.17 (CI: 0.06-0.49) for women who received combination therapy, and 0.24 (CI: 0.06-1.01) for women who received highly active antiretroviral therapy.
CONCLUSIONS:
RNA levels increased significantly from delivery to 12 weeks postpartum. Changes in HIV-1 RNA and CD4+ lymphocyte percentage were similar among women continuing or stopping therapy after delivery, and response to antiretroviral therapy was as expected postpartum.
AuthorsD Heather Watts, John Lambert, E Richard Stiehm, D Robert Harris, James Bethel, Lynne Mofenson, William A Meyer 3rd, Bonnie Mathieson, Mary Glen Fowler, George Nemo, PACTG 185 Study Team
JournalJournal of acquired immune deficiency syndromes (1999) (J Acquir Immune Defic Syndr) Vol. 33 Issue 5 Pg. 585-93 (Aug 15 2003) ISSN: 1525-4135 [Print] United States
PMID12902802 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anti-HIV Agents
  • HIV Antibodies
  • HIV hyperimmune globulin
  • Immunoglobulins, Intravenous
  • RNA, Viral
  • Zidovudine
Topics
  • Adult
  • Anti-HIV Agents (therapeutic use)
  • CD4 Lymphocyte Count
  • Combined Modality Therapy
  • Disease Progression
  • Female
  • HIV Antibodies (therapeutic use)
  • HIV Infections (complications, diagnosis, therapy)
  • HIV-1 (genetics, isolation & purification)
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Longitudinal Studies
  • Postpartum Period
  • Pregnancy
  • Pregnancy Complications, Infectious (diagnosis, therapy, virology)
  • Proportional Hazards Models
  • RNA, Viral (analysis)
  • Treatment Outcome
  • Zidovudine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: